register for a free guide

Subscribe via email today


28
May

The new weight loss drug Contrave, which is composed of naltrexone plus bupropion, is safe for women regardless of their menopausal status, according to the findings of  the two phase three studies conducted by Orexigen, the manufacturer of the said weight loss drug.

Contrave is made up of bupropion, a dopamine reuptake inhibitor and natrexone, an opioid receptor antagonist used for treating depression and alcohol dependence.

Last Frebruary 2011, Contrave was declined by FDA, saying that they still need a long-term clinical trial to show the safety of this weight loss drugs against heart attacks.

That trial will be presented in the upcoming American College of Obstetrics and Gynecology’s annual meeting in Washington DC this month (so cross your fingers!).

Contrave was proven in this study to cause a 6.2 percent weight reduction in the subjects’ original weight. These subjects have also showed improvement in their response to their food cravings and self control.

However, the most commonly noted side effects of this new weight loss drug include, gastrointestinal effects, nausea and headache. Contrave can also cause slight increase in pulses and blood pressure – the reason why FDA became a little too concerned.

Category : News

Write a Review of New Weight Loss Drug Effective in Women Regardless of Menopausal Status